Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVR OTCMKTS:BNXTF NASDAQ:PBYI NASDAQ:SGHT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVRAnteris Technologies Global$3.06+0.3%$4.02$2.34▼$8.79$110.35MN/A220,981 shs18,421 shsBNXTFBioNxt Solutions$0.40-3.7%$0.39$0.11▼$0.44$46.81M0.771,722 shs1,200 shsPBYIPuma Biotechnology$3.38-0.7%$3.41$2.23▼$4.13$167.75M1.29412,436 shs127,796 shsSGHTSight Sciences$3.50-0.1%$3.80$2.03▼$8.45$180.69M2.47206,665 shs46,839 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVRAnteris Technologies Global0.00%-4.09%-25.06%-2.87%+304,999,900.00%BNXTFBioNxt Solutions0.00%-4.17%+3.69%+34.80%+71.73%PBYIPuma Biotechnology0.00%+0.29%+6.58%+18.88%-7.10%SGHTSight Sciences0.00%+2.64%-13.79%+26.81%-54.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVRAnteris Technologies GlobalN/AN/AN/AN/AN/AN/AN/AN/ABNXTFBioNxt SolutionsN/AN/AN/AN/AN/AN/AN/AN/APBYIPuma Biotechnology4.2432 of 5 stars3.52.00.00.02.74.23.1SGHTSight Sciences1.5719 of 5 stars2.12.00.00.01.83.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVRAnteris Technologies Global 3.00Buy$16.50439.22% UpsideBNXTFBioNxt Solutions 0.00N/AN/AN/APBYIPuma Biotechnology 3.00Buy$7.00107.28% UpsideSGHTSight Sciences 2.29Hold$3.9312.54% UpsideCurrent Analyst Ratings BreakdownLatest BNXTF, AVR, PBYI, and SGHT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025SGHTSight SciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$3.00 ➝ $4.006/18/2025SGHTSight SciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.50 ➝ $4.005/22/2025SGHTSight SciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.20 ➝ $3.605/9/2025SGHTSight SciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$2.50 ➝ $3.00(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVRAnteris Technologies Global$2.49M44.26N/AN/A$1.74 per share1.76BNXTFBioNxt Solutions$20K2,340.67N/AN/A($0.05) per share-8.09PBYIPuma Biotechnology$230.50M0.73$0.85 per share3.99$1.88 per share1.80SGHTSight Sciences$79.87M2.26N/AN/A$1.72 per share2.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVRAnteris Technologies Global-$76.29MN/A0.00N/AN/AN/AN/AN/A8/12/2025 (Estimated)BNXTFBioNxt Solutions-$3.88M-$0.04N/A∞N/A-19,165.00%N/A-663.55%N/APBYIPuma Biotechnology$30.28M$0.774.398.89N/A16.37%49.35%18.25%7/30/2025 (Estimated)SGHTSight Sciences-$51.51M-$0.98N/AN/AN/A-63.24%-54.62%-34.92%7/30/2025 (Estimated)Latest BNXTF, AVR, PBYI, and SGHT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025PBYIPuma Biotechnology$0.11N/AN/AN/A$52.00 millionN/A8/7/2025Q2 2025SGHTSight Sciences-$0.25N/AN/AN/A$18.18 millionN/A6/26/2025Q1 2025BNXTFBioNxt SolutionsN/A-$0.01N/A-$0.01N/AN/A5/13/2025Q1 2025AVRAnteris Technologies GlobalN/A-$0.61N/A-$0.61N/AN/A5/8/2025Q1 2025SGHTSight Sciences-$0.29-$0.28+$0.01-$0.28$16.51 million$17.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVRAnteris Technologies GlobalN/AN/AN/AN/AN/ABNXTFBioNxt SolutionsN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ASGHTSight SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVRAnteris Technologies GlobalN/A3.673.65BNXTFBioNxt SolutionsN/A0.150.15PBYIPuma Biotechnology0.111.531.43SGHTSight Sciences0.5110.479.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVRAnteris Technologies GlobalN/ABNXTFBioNxt SolutionsN/APBYIPuma Biotechnology61.29%SGHTSight Sciences55.51%Insider OwnershipCompanyInsider OwnershipAVRAnteris Technologies GlobalN/ABNXTFBioNxt SolutionsN/APBYIPuma Biotechnology23.30%SGHTSight Sciences28.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVRAnteris Technologies Global13836.06 millionN/AN/ABNXTFBioNxt Solutions20115.76 millionN/ANot OptionablePBYIPuma Biotechnology20049.63 million38.07 millionOptionableSGHTSight Sciences21051.70 million36.76 millionOptionableBNXTF, AVR, PBYI, and SGHT HeadlinesRecent News About These CompaniesSight Sciences, Inc. (NASDAQ:SGHT) Given Consensus Rating of "Hold" by BrokeragesJuly 19 at 2:15 AM | marketbeat.comSight Sciences (NASDAQ:SGHT) Rating Lowered to Sell at Wall Street ZenJuly 19 at 2:27 AM | americanbankingnews.comWall Street Zen Downgrades Sight Sciences (NASDAQ:SGHT) to SellJuly 19 at 2:25 AM | marketbeat.comMorgan Stanley Increases Sight Sciences (NASDAQ:SGHT) Price Target to $4.00July 17, 2025 | americanbankingnews.com7SGHT : The Analyst Verdict: Sight Sciences In The Eyes Of 4...July 15, 2025 | benzinga.comSight Sciences (NASDAQ:SGHT) Given New $4.00 Price Target at Morgan StanleyJuly 15, 2025 | marketbeat.comSight Sciences, Inc. (NASDAQ:SGHT) Insider Matthew Link Sells 4,889 SharesJuly 8, 2025 | insidertrades.comInsider Selling: Sight Sciences, Inc. (NASDAQ:SGHT) Insider Sells 4,889 Shares of StockJuly 7, 2025 | marketbeat.comSight Sciences, Inc. (NASDAQ:SGHT) CTO Sells $23,681.43 in StockJuly 7, 2025 | marketbeat.comSight Sciences, Inc. (NASDAQ:SGHT) Insider Sells $38,197.20 in StockJuly 7, 2025 | marketbeat.comInsider Selling: Sight Sciences, Inc. (NASDAQ:SGHT) CEO Sells 23,637 Shares of StockJuly 7, 2025 | marketbeat.comSGHT - Sight Sciences Inc Chart - MorningstarJuly 5, 2025 | morningstar.comMWall Street Zen Upgrades Sight Sciences (NASDAQ:SGHT) to "Hold"June 28, 2025 | marketbeat.comSight Sciences Leads The Pack Of 3 Promising Penny StocksJune 24, 2025 | uk.finance.yahoo.comSight Sciences, Inc. (NASDAQ:SGHT) Given Average Recommendation of "Hold" by BrokeragesJune 24, 2025 | marketbeat.comsight sciences appoints new board member and holds annual meetingJune 7, 2025 | uk.investing.comSight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27thMay 14, 2025 | globenewswire.comSight Sciences stock holds as Needham reiterates ratingMay 11, 2025 | uk.investing.comSight Sciences, Inc. (SGHT) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comSight Sciences, Inc. (NASDAQ:SGHT) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comSight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue GuidanceMay 10, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBNXTF, AVR, PBYI, and SGHT Company DescriptionsAnteris Technologies Global NASDAQ:AVR$3.06 +0.01 (+0.33%) As of 11:14 AM EasternAnteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.BioNxt Solutions OTCMKTS:BNXTF$0.40 -0.02 (-3.67%) As of 07/18/2025 01:03 PM EasternBioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.Puma Biotechnology NASDAQ:PBYI$3.38 -0.02 (-0.68%) As of 11:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Sight Sciences NASDAQ:SGHT$3.50 -0.01 (-0.14%) As of 11:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Q2 Could Be the Catalyst PayPal Investors Have Been Waiting For Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.